Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 18, Topic 5
In Progress

Comprehensive Management of Rhabdomyolysis

Lesson Progress
0% Complete
De-escalation and Transition Planning in Rhabdomyolysis Recovery

De-escalation and Transition Planning in Rhabdomyolysis Recovery

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

Develop a plan to facilitate patient recovery, mitigate long-term complications, and ensure a safe transition of care.

1. Introduction

The recovery phase in rhabdomyolysis management shifts focus from aggressive resuscitation to restoring homeostasis and functional independence. Structured de-escalation and transition protocols are crucial to prevent complications such as rebound acute kidney injury (AKI), fluid overload, and Post-ICU Syndrome (PICS).

Key Interdisciplinary Goals:

  • Restore renal and muscle function without iatrogenic injury.
  • Minimize long-term morbidity, including chronic kidney disease and PICS.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Protocolized Weaning

Protocolized weaning of intravenous fluids and renal replacement therapy (RRT) reduces complications compared to ad-hoc withdrawal strategies.

2. Weaning and De-escalation of Intensive Therapies

Tapering intravenous (IV) fluids and renal replacement therapy (RRT) should be guided by objective criteria for renal recovery and meticulous monitoring protocols to avoid rebound injury or fluid imbalance.

Criteria for IV Fluid Tapering:

  • Urine output ≥0.5 mL/kg/hr sustained over 6–12 hours.
  • Downward-trending or normalized creatine kinase (CK) levels.
  • Stable or improving serum creatinine and electrolytes.
  • Hemodynamic stability off vasopressors.

Fluid Weaning Protocol

Figure 1: IV Fluid Weaning Protocol Flowchart
Start: Patient meets criteria for fluid tapering
1. Reduce maintenance fluids by 25–50% over 24 hours
2. Monitor hourly UO, daily weights, BUN/Cr, electrolytes
3. Targets Maintained? (UO ≥0.5 mL/kg/hr, stable labs)
4b. Revert to prior rate & reassess muscle injury
4a. Repeat reduction until goal volume (maintenance or PO)
End: Goal fluid volume achieved or transition to oral intake

RRT Discontinuation Triggers:

  • Native urine output >400 mL/day or consistently >0.5 mL/kg/hr.
  • Downward trajectory of serum creatinine and BUN.
  • Resolution of refractory hyperkalemia, metabolic acidosis, and significant volume overload.
  • Hemodynamic stability without escalating vasopressor requirements.

Loop Diuretics for Fluid Offloading:

Considered for patients who are euvolemic or mildly hypervolemic with evidence of some renal recovery, to facilitate fluid removal.

  • Agent: Furosemide is commonly used.
  • Mechanism: Inhibits the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the Loop of Henle.
  • Dosing: Initial dose of 20–80 mg IV bolus; may be titrated based on urine output response.
  • Monitoring: Closely monitor electrolytes (especially K⁺, Mg²⁺, Ca²⁺), volume status (daily weights, fluid balance), and hearing (risk of ototoxicity at high doses or rapid infusion).

Pitfall: If there is no significant diuresis after one to two appropriate bolus doses, discontinue loop diuretics to avoid potential adverse effects like electrolyte disturbances or worsening renal function in non-responsive patients.

Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearls for Weaning
  • Never abruptly stop IV fluids or RRT in critically ill patients; always use stepwise reductions and monitor closely.
  • Reserve diuretics for euvolemic or mildly hypervolemic patients who demonstrate some residual renal function and are likely to respond.

3. Conversion from Intravenous to Enteral Medications

An early switch from IV to enteral (oral or via feeding tube) medications supports gut integrity, reduces catheter-associated risks, and can lower healthcare costs. Medication choices must be tailored based on bioavailability, potential interactions with enteral feeds, and patient-specific factors.

Assess GI Tolerance:

  • Gastric residual volume <200 mL (if applicable).
  • Presence of active bowel sounds, absence of signs of ileus or obstruction.
  • Hemodynamic stability with minimal or no vasopressor support.

Select Enteral Access:

  • Nasogastric tube (NGT): Suitable for short-term use in patients with low aspiration risk.
  • Percutaneous endoscopic gastrostomy (PEG) tube: Preferred for long-term enteral access.
  • Post-pyloric tube (e.g., nasojejunal): Considered for patients at high risk of aspiration or with gastroparesis.

Enteral Conversion Considerations

Table 1: Examples of IV to Enteral Medication Conversion Considerations
Drug Class / Example Approx. Oral Bioavailability Potential Dose Adjustment Enteral Feed Interaction Key Monitoring
Levofloxacin ~99% Generally none (1:1 conversion) Yes (cations like Ca, Mg, Fe, Al can chelate; separate by 2 hrs) Renal function, QTc interval
Phenytoin Variable (70–90% for capsules) May need ↑ dose by 20–30% if switching from IV to suspension. Hold feeds 1-2h before/after. Yes (binds to feeds, reducing absorption) Serum trough levels, seizure activity
Warfarin >90% Monitor INR closely during transition Yes (Vitamin K in some formulas, binding to protein) INR
Metoprolol ~40-50% (tartrate) Oral dose typically higher than IV due to first-pass metabolism (e.g., IV 5mg ≈ PO 25-50mg) Minimal Heart rate, blood pressure
Morphine ~20-40% Oral dose significantly higher than IV (e.g., IV 10mg ≈ PO 30mg) Minimal Pain score, sedation, respiratory rate

Conversion Steps:

  • Hold enteral feeds 1–2 hours before and after administering drugs known for significant feed interactions (e.g., fluoroquinolones, phenytoin).
  • Adjust doses for differences in bioavailability and first-pass metabolism where indicated (e.g., beta-blockers, opioids).
  • Monitor drug levels (if applicable) or clinical effect within 24–48 hours of conversion to ensure therapeutic efficacy and safety.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: High Bioavailability Agents

Many antimicrobial agents, such as fluoroquinolones (e.g., levofloxacin, moxifloxacin) and linezolid, have excellent oral bioavailability (often >90%), permitting a 1:1 IV to enteral dose conversion, simplifying the switch.

4. Mitigation of Post-ICU Syndrome (PICS)

Post-ICU Syndrome (PICS) encompasses new or worsened impairments in physical, cognitive, and/or psychological function that arise after critical illness and persist beyond hospital discharge. Early identification of at-risk patients and proactive interventions are key to preserving long-term function.

High-Risk Features for PICS:

  • Age >65 years.
  • Duration of mechanical ventilation >7 days or use of deep sedation.
  • Presence of severe sepsis, ARDS, or multi-organ failure.
  • Pre-existing cognitive or functional impairments.

Early Mobilization:

  • Initiate within 24–48 hours of ICU admission or stabilization, as tolerated.
  • Daily physical therapy (PT) and occupational therapy (OT) consults: progress from passive range-of-motion exercises to active exercises, sitting at the edge of the bed, transferring to a chair, and ambulation.

Delirium Prevention and Management (ABCDEF Bundle)

Figure 2: The ABCDEF Bundle for ICU Liberation
A: Assess, Prevent, and Manage Pain

Regular pain assessment using validated scales; multimodal analgesia.

B: Both Spontaneous Awakening Trials (SATs) and Spontaneous Breathing Trials (SBTs)

Daily interruption of sedation and assessment for readiness to extubate.

C: Choice of Analgesia and Sedation

Target light sedation; use non-benzodiazepine sedatives when possible.

D: Delirium: Assess, Prevent, and Manage

Regular delirium screening (e.g., CAM-ICU); non-pharmacologic interventions.

E: Early Mobility and Exercise

Reduce immobility; progressive mobilization plan.

F: Family Engagement and Empowerment

Involve family in care; support communication and presence.

Nutritional & Psychosocial Support:

  • Dietitian-guided nutritional support, aiming for protein intake of 1.2–2.0 g/kg/day and appropriate caloric targets to prevent muscle wasting.
  • Psychological assessment and support; interventions for anxiety, depression, and PTSD.
  • Sleep hygiene interventions: promote normal sleep-wake cycles, minimize nighttime disruptions.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: ABCDEF Bundle Impact

Consistent implementation of the ABCDEF bundle has been shown to reduce delirium duration, shorten ICU and hospital length of stay, decrease mortality, and lessen the incidence and severity of PICS.

5. Medication Reconciliation and Discharge Counseling

Pharmacist-led medication reconciliation and comprehensive patient education are vital components of a safe transition from hospital to home, aiming to reduce medication errors and preventable readmissions.

Structured Medication Reconciliation:

  1. Compare Lists: Systematically compare the patient’s pre-admission medication list (home meds), medications administered during hospitalization, and the proposed discharge medication list.
  2. Resolve Discrepancies: Identify and resolve any discrepancies, including omissions, duplications, dosing errors, or drug interactions.
  3. Review Nephrotoxic Agents: Critically evaluate the need for and discontinue potentially nephrotoxic agents (e.g., NSAIDs, certain antibiotics) unless absolutely essential and no safer alternatives exist, especially in patients recovering from AKI. Statins, if indicated for cardiovascular risk, are generally continued.

Patient/Caregiver Education:

  • Clearly explain the indication, dosing schedule, administration instructions, potential side effects, and monitoring requirements for each discharge medication.
  • Educate on warning signs of recurrent rhabdomyolysis (e.g., new or worsening muscle pain/weakness, dark tea-colored urine) or AKI (e.g., decreased urine output, swelling).
  • Utilize the “teach-back” method to confirm understanding. Provide written materials tailored to the patient’s health literacy level.

Address Social Determinants of Health:

  • Verify insurance coverage for prescribed medications and inquire about affordability.
  • Confirm access to a local pharmacy for obtaining medications.
  • Involve social work or case management to address financial, transportation, or other socioeconomic barriers to care.

Follow-Up Planning:

  • Schedule outpatient laboratory tests (e.g., renal function panel, CK, electrolytes) within 7–14 days post-discharge, or sooner if clinically indicated.
  • Arrange specialist referrals as needed (e.g., nephrology for ongoing AKI/CKD management, physical therapy for rehabilitation, mental health services for PICS-related psychological issues).
  • Consider telehealth or home health visits for high-risk patients to monitor recovery and adherence.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Discharge Planning Impact

Comprehensive discharge planning that includes thorough medication reconciliation and patient-centered education significantly reduces post-discharge medication errors, adverse drug events, and hospital readmission rates.

References

  1. Kodadek L, Carmichael H, Sathyakumar K, et al. Rhabdomyolysis: A clinical practice guideline from the AAST Critical Care Committee. Trauma Surg Acute Care Open. 2022;7(1):e000836.
  2. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.
  3. Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician. 2002;65(5):907–912.
  4. Zeng X, Zhang L, Wu T, Fu P. Continuous renal replacement therapy (CRRT) for rhabdomyolysis. Cochrane Database Syst Rev. 2014;(6):CD008566.
  5. Better OS, Rubinstein I, Winaver J, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int. 1997;52(3):886–894.